エーザイ、11名の先端医療機関の専門家および8名のエーザイ研究者による「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果の論文がthe New England Journal of Medicineに掲載 Nov 30, 2022 17:30 JST Read More
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果を第15回アルツハイマー病臨床試験会議（CTAD）において発表 Nov 30, 2022 17:30 JST Read More
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference Nov 30, 2022 09:21 HKT/SGT Read More
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine Nov 30, 2022 08:31 HKT/SGT Read More
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Nov 29, 2022 18:28 HKT/SGT Read More
EC Healthcare Announces FY2022/23 Interim Results, Revenue Increased 31.1% YoY Mainly Driven by Medical Services Nov 24, 2022 13:02 HKT/SGT Read More
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting Nov 24, 2022 08:04 HKT/SGT Read More
